XELJANZ BLOOD CLOT ATTORNEYS

XELJANZ ATTORNEYS

About The Xeljanz attorneys in our network are investigating claims that Xeljanz is linked to cancer, blood clots, and cardiovascular issues.

Has your health been compromised after taking Xeljanz? If so, You may be entitled to significant compensation.

What to do when your drug makes you feel worse instead of better. Whether an OTC medication or a prescription by your healthcare provider, medications are meant to be used for a patient’s condition. However, when the side effects outweigh the benefits, drugs can turn extremely dangerous, sometimes deadly. Pharmaceutical companies and suppliers are ethically and legally responsible for adequately disclosing a drug’s risks and side effects before it is brought to market. Unfortunately, these caveats are often suppressed in the name of profits.

Pfizer’s Xeljanz (tofacitinib) has been on the market since 2012. First approved for rheumatoid arthritis, Xeljanz has since received FDA approval to treat other types of arthritis and ulcerative colitis. The FDA has, however, just issued a warning that Xeljanz may be connected to cancer, blood clots, and heart issues.

But one still wonders: Why did Pfizer not alert consumers to those potential risks earlier? The lawsuit against Xeljanz alleges Pfizer failed to provide proper notice of side effects of the drug, causing avoidable harm to patients suffering from pulmonary thrombi, heart attacks, strokes, breast and colon cancers, and other serious health problems.

Our dangerous drug lawyers take these cases on a contingency-fee-basis. This means that our clients pay nothing if we do not win. Call (888) 491-0444 to discuss your case at no cost with one of our lawyers that has experience with litigation pertaining to Xeljanz.

Xeljanz belongs to a class of drugs known as Janus-kinase inhibitors (JAKs). As Pfizer explained, our bodies have signaling proteins called cytokines that govern the immune system’s response; cytokine production increases when our body fights an infection.

Cytokine production is thought to play a role in chronic inflammatory conditions, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Xeljanz interrupts signals that produce some cytokines, which decreases inflammation. Specifically, Xeljanz blocks – or inhibits – the release of cytokines from the JAK signaling pathway.

Most Americans assume that if the FDA approves a medication, it has been rigorously evaluated for safety and effectiveness. Unfortunately, however, that is only sometimes the case.

In addition to clinical trials before approval, FDA can require studies after market studies as a condition for approving drugs. These studies collect additional information on the medicine’s safety, effectiveness, or best use. For example, when the FDA first approved Xeljanz in 2012, it ordered post-market safety studies, known as ORAL surveillance.

But instead of validating the safety of Xeljanz, the study led to more warnings and health advisories. In February 2019, FDA warned that ongoing safety trials for Xeljanz had found increased risks for pulmonary thrombi and deaths. In July 2019, FDA announced it had approved new warnings regarding blood clots and death in patients treated with the twice-daily, 10 mg dose of Xeljanz.

Thrombosis occurs when a clot blocks a vein or artery. Deep vein thrombosis, pulmonary embolism, and arterial thrombosis have been reported in patients with Xeljanz.

DVT – which stands for Deep vein thrombosis, is a blood clot in the veins deep inside the body (DVT). DVT frequently affects the legs.

A blood clot traveling to the lungs is called a pulmonary embolism (PE). PEs are often caused by a blood clot that starts in your arm or leg.

Artery thrombosis is a blood clot that forms in the arteries. This type of thrombosis can prevent blood from reaching the heart and other organs. Blood clots can cause a heart attack, stroke, organ damage, or even death.

The following big safety news from Xeljanzs post-marketing studies was as concerning. First, the FDA notified the public in February 2021 that preliminary results showed a higher cancer risk with Xeljanz. Also, in February 2021, FDA warned about severe heart problems that could occur from using Xeljanz.

In their press release, Pfizer called them “major adverse cardiovascular events” (MACE). Pfizer reports that 135 patients had significant adverse cardiovascular events in the trial, though the full results are yet to be released. The most commonly reported event was myocardial infarction.

Taking on giant drug companies requires the help of big legal firms. Our network of nationally recognized, best-practice litigation attorneys has the resources, power, and expertise to successfully challenge large drug companies such as Pfizer in the courts. And we take each case on a contingency-fee-basis, so our clients only pay a penny if we win money for them.

We are now talking with clients around the country about lawsuits over Xeljanz cancer, blood clots, and cardiovascular disease. Patients taking Xeljanz as prescribed who have developed malignancy, thrombosis, or a heart-related problem may qualify for the suit. Lawsuits against Pfizer may seek monetary damages for medical bills, lost wages, pain, suffering, decreased quality of life, and more. Call us today to talk to an attorney regarding your experience with Xeljanz. The number to call is (888) 491-0444 and we’re available 24/7.

Despite being sold as a safe drug, Xeljanz increases its users’ risk for blood clots, cancer, and cardiovascular problems. The FDA approved the medication when it was released, but post-market safety studies concluded the side effects were more harmful than initially believed. Unfortunately, Pfizer’s company in charge of the medication knew the side effects before the safety study. Still, it failed to disclose that information to the public, trying to keep its profits. Unfortunately, this unethical conduct exposed thousands of consumers to a higher risk of harm, making their actions unsustainable.

Why is Xeljanz a Dangerous Drug? Xeljanz was first introduced into the market in 2012, and it is only now that we realize how serious the side effects are. The drug is unlike traditional products in that the results are all biological, meaning that impact is ingested, making recovery even harder if injured. The magnitude of the Xeljanz side effects makes it incredibly dangerous for consumers. The company’s refusal to disclose risks makes this worse, as many are unaware of the increased risks they are taking.

Frequently Asked Questions About Xeljanz